IMNM Immunome Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472012 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-63.3%
TTM net income YoY-9.5%
TTM EPS YoY20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,947.9%
Net margin-5,593.8%
FCF margin-5,118.9%
EBITDA margin-5,886.7%
Returns
ROE-50.1%
ROA-46.7%
ROIC (approx.)-679.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.0%
Debt / equity0.00x
Current ratio21.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue224.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $4.01M | $2.93M | $2.74M |
| R&D expense | $69.51M | $59.88M | $46.38M | $50.77M | $49.19M | $40.45M | $36.87M | $47.89M |
| SG&A expense | $20.86M | $18.25M | $12.95M | $12.09M | $10.95M | $10.04M | $10.69M | $10.45M |
| Operating income | -$90.36M | -$78.14M | -$59.33M | -$72.86M | -$60.14M | -$46.48M | -$44.64M | -$82.97M |
| Net income | -$85.78M | -$73.13M | -$53.84M | -$69.90M | -$57.46M | -$43.40M | -$41.64M | -$80.25M |
| EBITDA | -$89.36M | -$77.18M | -$58.73M | -$72.23M | -$59.55M | -$45.84M | -$44.02M | -$82.52M |
| EPS (basic) | -0.76 | -0.65 | -0.48 | — | -0.65 | -0.50 | -0.52 | — |
| EPS (diluted) | -0.76 | -0.65 | -0.48 | — | -0.65 | -0.50 | -0.52 | — |
| Weighted avg. shares (diluted) | 113.56M | 113.27M | 113.14M | — | 87.96M | 87.01M | 79.41M | — |
| Banking | ||||||||
| Net interest income | $4.58M | $5.01M | $5.49M | $2.96M | $2.68M | $3.08M | $3.00M | $2.72M |
| Balance sheet | ||||||||
| Cash & equivalents | $212.84M | $217.71M | $582.69M | $653.48M | $272.64M | $143.88M | $257.61M | $143.45M |
| Short-term investments | $248.74M | $302.29M | — | $0 | $0 | $124.16M | $59.71M | $73.95M |
| Current assets | $477.80M | $538.45M | $594.31M | $660.78M | $279.92M | $277.43M | $323.13M | $221.34M |
| PP&E, net | $16.67M | $17.36M | $17.08M | $14.64M | $11.56M | $11.03M | $10.95M | $10.11M |
| Total assets | $505.53M | $565.38M | $619.79M | $683.19M | $299.38M | $296.29M | $342.69M | $240.24M |
| Current liabilities | $40.97M | $35.71M | $27.41M | $44.99M | $31.45M | $22.88M | $30.80M | $54.31M |
| Total liabilities | $51.22M | $40.30M | $31.11M | $48.84M | $35.46M | $27.02M | $35.57M | $59.08M |
| Shareholders' equity | $454.30M | $525.08M | $588.69M | $634.34M | $263.92M | $269.27M | $307.13M | $181.16M |
| Shares outstanding | 113.65M | 113.40M | 113.17M | 113.13M | 91.71M | 87.01M | 86.96M | 64.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$60.75M | -$61.69M | -$58.64M | -$47.95M | -$40.51M | -$49.40M | -$53.05M | -$42.06M |
| Capital expenditure | $489,000 | $2.18M | $3.00M | $4.00M | $1.12M | $905,000 | $3.67M | $1.13M |
| Free cash flow | -$61.24M | -$63.87M | -$61.64M | -$51.95M | -$41.63M | -$50.31M | -$56.72M | -$43.19M |
| Investing cash flow | $53.51M | -$304.35M | -$12.02M | -$4.00M | $123.88M | -$64.17M | $5.09M | $9.76M |
| Financing cash flow | $2.38M | $1.06M | -$135,000 | $432.80M | $45.39M | -$55,000 | $162.23M | $20.09M |
| Depreciation & amortization | $1.00M | $957,000 | $603,000 | $629,000 | $589,000 | $637,000 | $611,000 | $450,000 |
| Stock-based compensation | $12.76M | $8.80M | $7.95M | $7.89M | $6.75M | $5.35M | $5.70M | $5.47M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.